Kuemmerle-Deschner JB et al. – Recombinant human IFN- α2a (RhIFN-α2a) was effective and well tolerated in the juvenile patients with severe neurological Behçet's disease (BD). Inspite of serious consequences following ocular and central nervous system (CNS) affection and adverse effects of steroid dependency, administration of rhIFN-α2a at an earlier time point needs to be considered. Methods
To report the successful treatment with rhIFN-α2a in 2 male adolescents suffering from severe treatment-resistant BD with CNS involvement
The pts were 14- and 15-yrs old
RhIFN-α2a was administered initially at 3 million IU/dx4wks followed by 3 x 3 million IU/wk
Results
Complete remission was achieved in Patient 1
Patient 2 experienced remarkable improvement
In both pts the MRI lesions improved
Patient 2 had mild flu-like symptoms as adverse effect
See all
